PE88699A1 - Formas de dosificacion de liberacion sostenida de sertralina - Google Patents

Formas de dosificacion de liberacion sostenida de sertralina

Info

Publication number
PE88699A1
PE88699A1 PE1998000572A PE00057298A PE88699A1 PE 88699 A1 PE88699 A1 PE 88699A1 PE 1998000572 A PE1998000572 A PE 1998000572A PE 00057298 A PE00057298 A PE 00057298A PE 88699 A1 PE88699 A1 PE 88699A1
Authority
PE
Peru
Prior art keywords
sertraline
compressed
sustained release
dosage forms
mga
Prior art date
Application number
PE1998000572A
Other languages
English (en)
Inventor
Ende Mary Tanya Am
William John Curatolo
Hylar Lewis Friedman
James Blair West
Scott Max Herbig
Ravi Mysore Shanker
Dwayne Thomas Friesen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE88699A1 publication Critical patent/PE88699A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Abstract

SE REFIERE A UNA FORMA DE DOSIFICACION QUE LIBERA SERTRALINA A UNA VELOCIDAD NO SUPERIOR A 0,8 mgA/h/Kg, NO LIBERANDO MAS DEL 70% DE SERTRALINA EN LA PRIMERA HORA, Y LUEGO LIBERANDOLA A UNA VELOCIDAD DE 0,02 mgA/h/Kg LA LIBERACION SOSTENIDA SE DESENCADENA POR EL pH. LA SERTRALINA SE ENCUENTRA COMO BASE LIBRE, CLORHIDRATO, ACETATO, ASPARTATO O LACTATO; SIENDO SENSIBLE A LAS ENZIMAS. LAS FORMAS DE DOSIFICACION SE PRESENTAN COMO COMPRIMIDO DE MATRIZ QUE PERMANECE INTACTO DURANTE EL PERIODO DE LIBERACION SOSTENIDA, COMPRIMIDO DE MATRIZ DISGREGABLE, COMPRIMIDO DE MATRIZ PARCIALMENTE RECUBIERTO CON UN POLIMERO QUE IMPIDE LA LIBERACION DE SERTRALINA, COMPRIMIDO OSMOTICO, COMPRIMIDO CON HIDROGEL, SISTEMA MULTIPARTICULAR RECUBIERTO CON UNA MEMBRANA Y BASADO EN LA DIFUSION. LA MEMBRANA TIENE UN LIQUIDO HIDROFOBO DENTRO DE LOS POROS DE LA MISMA. EL LIQUIDO ES IMPERMEABLE AL AGUA Y A LA SERTRALINA, SE MODIFICA POR DEGRADACION ENZIMATICA, SIENDO PERMEABLE AL AGUA Y A LA SERTRALINA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LA COMPOSICION SE PUEDE UTILIZAR PARA EL TRATAMIENTO DE LA ENFERMEDAD PSIQUIATRICA, EYACULACION PRECOZ, DEPENDENCIA QUIMICA
PE1998000572A 1997-07-01 1998-06-26 Formas de dosificacion de liberacion sostenida de sertralina PE88699A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5149897P 1997-07-01 1997-07-01
US5141497P 1997-07-01 1997-07-01
US5140297P 1997-07-01 1997-07-01
US5142097P 1997-07-01 1997-07-01

Publications (1)

Publication Number Publication Date
PE88699A1 true PE88699A1 (es) 1999-09-20

Family

ID=27489408

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000572A PE88699A1 (es) 1997-07-01 1998-06-26 Formas de dosificacion de liberacion sostenida de sertralina

Country Status (33)

Country Link
US (1) US6517866B1 (es)
EP (1) EP0999830A1 (es)
JP (1) JP2000514101A (es)
KR (2) KR100446366B1 (es)
CN (1) CN1256085C (es)
AP (1) AP1526A (es)
AR (2) AR015919A1 (es)
AU (1) AU739261B2 (es)
BG (1) BG103915A (es)
BR (1) BR9810403A (es)
CA (1) CA2290966C (es)
CO (1) CO4940402A1 (es)
DZ (1) DZ2546A1 (es)
EA (1) EA002482B1 (es)
HK (1) HK1026630A1 (es)
HR (1) HRP980379B1 (es)
HU (1) HUP0002296A3 (es)
ID (1) ID23503A (es)
IL (2) IL152330A0 (es)
IS (1) IS5265A (es)
MY (1) MY129175A (es)
NO (1) NO996518L (es)
NZ (2) NZ513456A (es)
OA (1) OA11245A (es)
PA (1) PA8454401A1 (es)
PE (1) PE88699A1 (es)
PL (1) PL337806A1 (es)
SK (1) SK180499A3 (es)
TN (1) TNSN98125A1 (es)
TR (1) TR199903280T2 (es)
TW (1) TWI241188B (es)
UY (1) UY25067A1 (es)
WO (1) WO1999001121A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
EP1067910B1 (en) * 1998-04-03 2004-05-26 Egalet A/S Controlled release composition
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
CA2698347A1 (en) * 1999-05-20 2000-11-30 Elan Pharma International Limited Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
EP1225881B1 (en) * 1999-09-03 2006-02-22 APBI Holdings, LLC The use of dapoxetine, a rapid-onset selective serotonin reuptake inhibitor, for treating sexual dysfunction
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
WO2001047498A2 (en) 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
US6620431B1 (en) * 2000-04-17 2003-09-16 Charles Signorino Shellac film coatings providing release at selected pH and method
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
BR0113626A (pt) 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
SE0004671D0 (sv) 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
JP2002212062A (ja) * 2001-01-24 2002-07-31 Teijin Ltd 遅延放出制御組成物
KR20030079990A (ko) * 2001-02-15 2003-10-10 가부시키가이샤산와카가쿠켄큐쇼 신규 안과용 조성물
MXPA03009588A (es) * 2001-04-18 2004-12-06 Nostrum Pharmaceuticals Inc Un recubrimiento novedoso para una composicion farmaceutica de liberacion sostenida.
AU2002316020B2 (en) * 2001-07-16 2007-03-15 Astrazeneca Ab Pharmaceutical formulation comprising a proton pump inhibitor and antacids
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
BR0212951A (pt) * 2001-09-28 2004-10-26 Mcneil Ppc Inc Formas de dosagens compósitas
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20100189797A1 (en) 2002-06-10 2010-07-29 Julien Mendlewicz Oral antidepressant formulation
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20040087661A1 (en) * 2002-09-16 2004-05-06 Sepracor, Inc. Treatment of CNS disorders with trans 4-3(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
WO2004065348A1 (en) * 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
EP1599212A4 (en) * 2003-02-14 2006-02-08 Combinatorx Inc POLYTHERAPY FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISORDERS
ES2570454T3 (es) 2003-03-26 2016-05-18 Egalet Ltd Sistema de liberación controlada de morfina
CA2520321A1 (en) * 2003-04-04 2004-10-14 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
US8168218B2 (en) 2003-04-24 2012-05-01 Jagotec Ag Delayed release tablet with defined core geometry
EP1626950A4 (en) * 2003-05-23 2007-05-23 Transform Pharmaceuticals Inc SERTRALINZUSAMMENSETZUNGEN
RS20060132A (en) * 2003-08-08 2008-06-05 Biovail Laboratories International Srl., Modified-release tablet of bupropion hydrochloride
DE602004027401D1 (de) * 2003-11-04 2010-07-08 Cipla Ltd Verfahren zur herstellung von polymorphen von sertralin hydrochlorid
TW201240679A (en) * 2004-03-12 2012-10-16 Capsugel Belgium Nv Pharmaceutical formulations
KR100772980B1 (ko) * 2004-04-01 2007-11-02 한미약품 주식회사 메트포르민의 경구투여용 서방성 제제
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
ITMI20041295A1 (it) * 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
CN101884626A (zh) 2004-08-13 2010-11-17 贝林格尔.英格海姆国际有限公司 包含普拉克索或其可药用盐的延长释放片剂、其制备方法及用途
KR100920856B1 (ko) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
WO2006072878A1 (en) * 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
US20080274183A1 (en) * 2005-02-04 2008-11-06 Phillip Michael Cook Thermoplastic articles containing a medicament
CN101146521A (zh) * 2005-03-14 2008-03-19 太阳医药高级研究有限公司 提供包含纤维素和甲基丙烯酸衍生物包衣的口服药物输送系统
US20090274759A1 (en) * 2005-06-03 2009-11-05 Egalet A/S Solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
US8747897B2 (en) * 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
US7893053B2 (en) * 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
WO2008015018A1 (en) 2006-08-03 2008-02-07 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
CA2930487A1 (en) * 2007-01-16 2008-07-24 Egalet Ltd. Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i)mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
AU2009281537A1 (en) * 2008-08-14 2011-06-30 Bioneer A/S Coated tablets with a remaining degradation surface over the time
DE102008051572A1 (de) 2008-09-05 2010-03-11 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Herstellung von Phosphatbindern und auf diese Weise hergestellte Phosphatbinder
AU2008243202B2 (en) * 2008-11-11 2015-08-20 Cosmo Technologies Ltd Oral antimicrobial pharmaceutical compositions
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
EP2498763A4 (en) 2009-11-09 2015-10-07 Spotlight Technology Partners Llc HYDROGELS BASED ON POLYSACCHARIDE
WO2011057133A1 (en) 2009-11-09 2011-05-12 Spotlight Technology Partners Llc Fragmented hydrogels
BR112015000150A2 (pt) 2012-07-06 2017-06-27 Egalet Ltd composições farmacêuticas dissuasoras de abuso de liberação controlada
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
WO2016020936A2 (en) * 2014-07-21 2016-02-11 Patel Jayendrakumar Dasharathlal A novel oral gastroretentive pharmaceutical dosage form
CN104402705B (zh) * 2014-11-04 2017-04-12 成都理工大学 球形柠檬酸钙及其制备方法和应用
JP6455293B2 (ja) * 2015-04-21 2019-01-23 ニプロ株式会社 セルトラリン及び／又はその薬学上許容しうる塩を含む製剤
ES2904834T3 (es) * 2017-10-05 2022-04-06 Purac Biochem Bv Polvo de lactato y método para su preparación
CN109432038A (zh) * 2018-12-28 2019-03-08 乐普制药科技有限公司 一种含有盐酸舍曲林的肠溶片剂及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US5112619A (en) 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4797286A (en) 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4847092A (en) 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4803076A (en) 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
DE3700420A1 (de) * 1986-12-22 1988-07-07 Efka Werke Kiehn Gmbh Fritz Tabakerzeugnis fuer die selbstverfertigung einer zigarette, insbesondere filter-zigarette
US5135947A (en) 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
US4777288A (en) 1987-06-11 1988-10-11 Pfizer Inc. Process for preparing a 4,4-diphenylbutanoic acid derivative
US4792448A (en) 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4839104A (en) 1987-06-11 1989-06-13 Pfizer, Inc. Process for preparing sertraline intermediates
US4971998A (en) 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
US4876282A (en) 1987-11-25 1989-10-24 Eli Lilly And Company 1-Phenylalkylamines as selective serotonin uptake inhibitors
US4855500A (en) 1988-05-04 1989-08-08 Pfizer Inc. Process for preparing a ketimine
US5026707A (en) 1988-05-23 1991-06-25 Eli Lilly And Company Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane
IL93464A (en) 1989-02-27 1996-10-16 Lilly Co Eli 2-Amino-1,2,3,4-Tetrahydronaplanin and 3 aminochromes with a transformed ring, a process for their preparation and pharmaceutical preparations containing them
US4981870A (en) 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US4983401A (en) 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings
US5130338A (en) 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
US4940731A (en) 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
ATE96999T1 (de) 1989-08-30 1993-11-15 Pfizer Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen.
US4962128A (en) 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
WO1992000103A1 (en) 1990-06-28 1992-01-09 Beecham Group Plc Pharmaceutical preparations
ATE118345T1 (de) 1990-08-07 1995-03-15 Pfizer Verwendung von interfacial polymerisierten membranen in abgabevorrichtungen.
WO1992002215A1 (en) 1990-08-09 1992-02-20 Massachusetts Institute Of Technology Method for treating the premenstrual or late luteal phase syndrome
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
WO1992009281A2 (en) 1990-11-24 1992-06-11 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
ATE197145T1 (de) 1991-02-08 2000-11-15 Lilly Co Eli Ringsubstituierte 2-amino-1,2,3,4- tetrahydronaphtahline und 3-aminochromane
AU1919592A (en) 1991-04-16 1992-11-17 National Institutes Of Health Method of treating trichotillomania and onychophagia
US5196607A (en) 1992-02-14 1993-03-23 Pfizer Inc. Process for preparing ketone enantiomer
CA2132012C (en) 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
IE930485A1 (en) 1993-06-28 1994-12-28 Hemisphere Ltd Antidepressant agents with a rapid onset of action
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DE69525847T2 (de) 1994-09-19 2002-09-05 Du Pont Pharm Co Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
DE69626916T2 (de) 1995-07-17 2003-10-09 Pfizer Sertralin zur Behandlung von Post-Myocard-Infarkt-Patienten
GB9514842D0 (en) 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
CA2250187A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Composition comprising olanzapine and a drug useful in the treatment of pain for use in the treatment of pain
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.
US5741807A (en) 1996-09-27 1998-04-21 Cytos Pharmaceuticals, L.P. Histidine compositions and methods for treating or preventing infectious and non-infectious diarrheas
US6590083B1 (en) 1999-04-16 2003-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials

Also Published As

Publication number Publication date
JP2000514101A (ja) 2000-10-24
PL337806A1 (en) 2000-09-11
HRP980379B1 (en) 2003-04-30
HK1026630A1 (en) 2000-12-22
ID23503A (id) 2000-04-27
TR199903280T2 (xx) 2000-11-21
IL133080A0 (en) 2001-03-19
KR20040004367A (ko) 2004-01-13
KR100412327B1 (ko) 2003-12-31
CA2290966A1 (en) 1999-01-14
HUP0002296A2 (hu) 2001-10-28
KR20010014043A (ko) 2001-02-26
US6517866B1 (en) 2003-02-11
CA2290966C (en) 2005-12-20
SK180499A3 (en) 2001-08-06
EA002482B1 (ru) 2002-06-27
NO996518L (no) 2000-02-29
NZ501251A (en) 2001-09-28
TWI241188B (en) 2005-10-11
EA199900964A1 (ru) 2000-08-28
NZ513456A (en) 2003-02-28
IL152330A0 (en) 2003-05-29
DZ2546A1 (fr) 2003-02-08
AP9801281A0 (en) 1998-06-30
AU7544998A (en) 1999-01-25
CN1261793A (zh) 2000-08-02
EP0999830A1 (en) 2000-05-17
TNSN98125A1 (fr) 2005-03-15
KR100446366B1 (ko) 2004-09-01
WO1999001121A1 (en) 1999-01-14
MY129175A (en) 2007-03-30
PA8454401A1 (es) 2000-05-24
BG103915A (en) 2000-07-31
CO4940402A1 (es) 2000-07-24
HRP980379A2 (en) 1999-04-30
HUP0002296A3 (en) 2001-11-28
UY25067A1 (es) 2000-12-29
BR9810403A (pt) 2000-08-29
AU739261B2 (en) 2001-10-11
AP1526A (en) 2006-01-03
CN1256085C (zh) 2006-05-17
AR065827A2 (es) 2009-07-08
IS5265A (is) 1999-11-23
NO996518D0 (no) 1999-12-28
AR015919A1 (es) 2001-05-30
OA11245A (en) 2003-07-23

Similar Documents

Publication Publication Date Title
PE88699A1 (es) Formas de dosificacion de liberacion sostenida de sertralina
GT200000222A (es) Forma de dosificacion de farmacos accionada por un hidrogel.
PA8524901A1 (es) Forma de dosificaciòn de fàrmaco activada por hidrogel
PE20000721A1 (es) Articulo absorbente que incluye un agente modificador de heces basado en calcio
DK0558475T3 (da) Fremgangsmåde og sammensætning til styret afgivelse af biologisk aktive midler
PT1165053E (pt) Formas de dosagem de dispersao rapida contendo gelatina de peixe
UY24210A1 (es) Composicion de gel o de barra antitranspirante libre de pegajosidad, clara o translucida y metodo de fabricacion
DE60334924D1 (de) Anoteilchengrösse
CO5210862A1 (es) Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
BR0113643A (pt) Compostos de guanidinobenzamidas como agonistas de mc4-r e seus usos
HK1060045A1 (en) Formulations comprising ibuprofen and diphenhydramine and the use thereof for the treatment of sleepdisturbances
ES2059786T3 (es) Composicion blanqueante.
AR065072A2 (es) Una formulacion medicamentosa de pellet de difusion controlada que tiene liberacion controlada de un compuesto activo
CO5251434A1 (es) Composicion de liberacion controlada
AR028705A1 (es) Bis-arilsulfonas
BR0003231A (pt) Catalisadores de leito fixo
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
AR029688A1 (es) Composiciones de liberacion retardada de matriz antibiotica de quinolona para administracion oral, y procedimiento para su fabricacion
BRPI0517245A (pt) suspensão farmacêutica e de acetaminofeno isentas de corantes
PE84399A1 (es) Formas de dosificacion de sertralina de liberacion retardada
BR0009771A (pt) Utilização de derivados de bisindóis indigóides capazes de penetrarem na membrana de células
IS6654A (is) Stöðugt gabapentín með pH innan stýrðra marka
PE20010568A1 (es) Formulaciones orales de liberacion controlada
PE20070464A1 (es) Forma farmaceutica con liberacion sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del ph
AR050628A1 (es) Composicion farmaceutica

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed